MARKET

OVID

OVID

Ovid
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.310
-0.080
-3.35%
Closed 16:00 10/18 EDT
OPEN
2.400
PREV CLOSE
2.390
HIGH
2.440
LOW
2.300
VOLUME
161.87K
TURNOVER
--
52 WEEK HIGH
6.61
52 WEEK LOW
1.530
MARKET CAP
110.17M
P/E (TTM)
-1.2541
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OVID and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

OVID News

  • Will Ovid Therapeutics Continue to Surge Higher?
  • Zacks.3d ago
  • Jeremy Levin Is The Chairman & CEO of Ovid Therapeutics Inc. (NASDAQ:OVID) And They Just Spent US$150k On Shares
  • Simply Wall St..10/12 14:25
  • Ovid Therapeutics, Sunrun, Pure Cycle, and Other 13D Filings
  • Barrons.com.10/12 01:23
  • 50 Biggest Movers From Yesterday
  • Benzinga.10/10 09:18

More

Industry

Biotechnology & Medical Research
-1.17%
Pharmaceuticals & Medical Research
-0.94%

Hot Stocks

Name
Price
%Change

About OVID

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
More

Webull offers Ovid Therapeutics Inc (OVID) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.